IgA Nephropathy (Berger’s Disease) is an indication for drug development with over 40 pipeline drugs currently active. According to GlobalData, preregistered drugs for IgA Nephropathy (Berger’s Disease) have a 100% likelihood of approval (LoA) indication benchmark. GlobalData’s report assesses how phase transition success rate (PTSR) and likelihood of approval (LoA) scores for pipeline drugs in IgA Nephropathy (Berger’s Disease) compared to historical benchmarks. Buy the report here.
Smarter leaders trust GlobalData
GlobalData tracks drug-specific phase transition and likelihood of approval scores, in addition to indication benchmarks based off 18 years of historical drug development data. Attributes of the drug, company and its clinical trials play a fundamental role in drug-specific PTSR and likelihood of approval.
IgA Nephropathy (Berger’s Disease) overview
IgA nephropathy, also known as Berger’s disease, is a kidney disorder characterized by the buildup of the antibody immunoglobulin A (IgA) in the small blood vessels (glomeruli) within the kidneys. This condition can lead to inflammation, damage, and scarring of the kidneys, affecting their ability to filter waste and excess fluids from the blood. The exact cause of IgA nephropathy is not fully understood, but it is believed to involve an abnormal immune system response, where the body produces IgA antibodies that are not effectively cleared from the bloodstream and deposit in the kidneys. Genetic and environmental factors may also contribute to its development. IgA nephropathy may initially present without noticeable symptoms, but as the disease progresses, individuals may experience blood in the urine (hematuria), which may be visible or detected through urine tests; proteinuria, or the presence of excess protein in the urine; high blood pressure; and swelling in the hands, feet, face, or abdomen due to fluid retention (edema).
For a complete picture of PTSR and LoA scores for drugs in IgA Nephropathy (Berger’s Disease), buy the report here.
Data Insights
From
The gold standard of business intelligence.
Blending expert knowledge with cutting-edge technology, GlobalData’s unrivalled proprietary data will enable you to decode what’s happening in your market. You can make better informed decisions and gain a future-proof advantage over your competitors.
GlobalData, the leading provider of industry intelligence, provided the underlying data, research, and analysis used to produce this article.
GlobalData’s Likelihood of Approval analytics tool dynamically assesses and predicts how likely a drug will move to the next stage in clinical development (PTSR), as well as how likely the drug will be approved (LoA). This is based on a combination of machine learning and a proprietary algorithm to process data points from various databases found on GlobalData’s Pharmaceutical Intelligence Center.
